The Daiichi Sankyo-Ranbaxy Laboratories deal has come as a shot in the arm for India’s Comprehensive Economic Co-operation Agreement (CECA) negotiations with Japan. Indian pharma companies have been unable to break into Japan, the world’s second largest drug market, due to the country’s stringent sanitary and phytosanitary standards, technical barriers to trade (TBT) and environmental norms.
Unlike India, most Asean countries have a very robust regime of quality and safety standards for products imported into their markets. What that means under an India-ASEAN FTA is that Indian manufacturers, despite having lower entry tariffs into Asean, will still not be able to export their products unless they meet the strict safety and quality regulations of those countries.
The labelling of genetically modified (GM) goods within Malaysia has come further under the spotlight this week as the industry remains torn between its proposed bio-safety laws and free trade agreements between the US.
Thai shrimp farmers have urged the government to speed up negotiations with Australia over its proposed health and safety standard before it comes into effect on February 21.
Information sheets from USTR